GlassScriptPhysician profile
Kapil Chatrath
NPI 1073578175
$14,143.80
in general payments reported to CMS, 2019-2025
28 companies · $3,495 in 2025
The $3,495 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,839 · 2020: $1,122 · 2021: $1,638 · 2022: $1,389 · 2023: $2,038 · 2024: $2,622 · 2025: $3,495.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,156.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,155.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $4,452.49 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,260.15 | 2019-2025 | Jardiance, Stiolto Respimat, Spiriva Respimat |
| Novo Nordisk INC | $1,205.48 | 2019-2024 | Ozempic, Rybelsus |
| Lilly USA, LLC | $1,182.96 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $995.16 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Amgen INC. | $840.08 | 2022-2025 | Repatha, Otezla, Repatha |
| Pfizer INC. | $607.39 | 2020-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $561.10 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $510.07 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $379.07 | 2019-2025 | Eliquis, Camzyos |
| Sanofi-Aventis U.S. LLC | $326.53 | 2019-2023 | |
| Amarin Pharma, INC. | $309.83 | 2019-2022 | |
| Sk Life Science, INC. | $279.95 | 2025 | Xcopri |
| Astellas Pharma US INC | $219.98 | 2021 | |
| Merck Sharp & Dohme LLC | $179.40 | 2019-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $157.05 | 2019-2025 | Linzess, Viberzi |
| Abbott Laboratories | $153.68 | 2021-2025 | Freestyle Libre 3 |
| Exact Sciences Corporation | $114.71 | 2023-2025 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $92.78 | 2019-2021 | |
| Ge Healthcare | $66.74 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $58.88 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $45.23 | 2023 | Voquezna |
| Esperion Therapeutics, INC. | $41.81 | 2020-2021 | |
| Amphastar Pharmaceuticals, INC. | $31.98 | 2025 | |
| Ultragenyx Pharmaceutical INC. | $20.36 | 2020 | |
| Dexcom, INC. | $18.27 | 2024 | Dexcom G6 Transmitter |
| Eisai INC. | $17.93 | 2021 | |
| Shield Therapeutics INC | $14.74 | 2023 | Accrufer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kapil Chatrath listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.